Indivior Announces BARDA's First Order Of OPVEE Nasal Spray To Combat Opioids And Aid In National Preparedness; BARDA Will Use $8.7M In Project BioShield Designated Funding For The Initial Procurement
Portfolio Pulse from Benzinga Newsdesk
Indivior PLC has announced that BARDA has placed its first order for OPVEE nasal spray, a nalmefene opioid overdose reversal product, using $8.7 million in Project BioShield funding. This order aims to enhance national preparedness against synthetic opioid emergencies.
August 26, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior PLC has secured a significant order from BARDA for its OPVEE nasal spray, marking a crucial step in addressing synthetic opioid emergencies. This $8.7 million order under Project BioShield funding highlights the importance of OPVEE in national preparedness efforts.
The order from BARDA represents a significant endorsement and financial commitment to Indivior's OPVEE nasal spray, likely boosting investor confidence and potentially increasing the stock price in the short term. The focus on national preparedness and the unique positioning of OPVEE as a treatment for synthetic opioids like fentanyl further underscores its market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100